A large analysis combined data from 5,127 patients with cervical cancer to look at a specific blood marker called the lymphocyte-to-monocyte ratio, or LMR. This ratio compares two types of white blood cells found in the blood. The researchers found that patients with a low LMR before starting treatment had worse survival rates compared to those with a higher ratio. This link held true even after adjusting for other factors that might influence health outcomes.
The study tracked these patients for a very long time, with a total follow-up period of 50 years. During this time, the data showed that low LMR was connected to both shorter overall survival and shorter progression-free survival. This means the cancer was more likely to grow or spread in people with the lower blood marker.
While this finding is promising, the study has some limits. The researchers noted that future studies need to confirm these results and find the best ways to measure this marker in real clinical settings. They also want to see if this simple blood test can help doctors better predict which patients might need more aggressive care. Until more prospective studies are done, this marker should be seen as a potential tool rather than a definitive rule.